SG11201702075QA - Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms) - Google Patents

Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)

Info

Publication number
SG11201702075QA
SG11201702075QA SG11201702075QA SG11201702075QA SG11201702075QA SG 11201702075Q A SG11201702075Q A SG 11201702075QA SG 11201702075Q A SG11201702075Q A SG 11201702075QA SG 11201702075Q A SG11201702075Q A SG 11201702075QA SG 11201702075Q A SG11201702075Q A SG 11201702075QA
Authority
SG
Singapore
Prior art keywords
kdms
modulating
catalytic activity
histone lysine
lysine demethylases
Prior art date
Application number
SG11201702075QA
Other languages
English (en)
Inventor
Myeong-Seop Kim
Taesun Park
Taeyoung Yoon
Seung Min Yang
Hae-Sun Kim
Jun Gyu Kim
Original Assignee
Dong A St Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A St Co Ltd filed Critical Dong A St Co Ltd
Publication of SG11201702075QA publication Critical patent/SG11201702075QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
SG11201702075QA 2014-10-29 2015-10-27 Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms) SG11201702075QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462069915P 2014-10-29 2014-10-29
PCT/KR2015/011386 WO2016068580A2 (fr) 2014-10-29 2015-10-27 Nouveaux composés de pyridopyrimidinone pour moduler l'activité catalytique des histone lysine déméthylases (kdm)

Publications (1)

Publication Number Publication Date
SG11201702075QA true SG11201702075QA (en) 2017-04-27

Family

ID=55851908

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201702075QA SG11201702075QA (en) 2014-10-29 2015-10-27 Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)

Country Status (13)

Country Link
US (1) US9834550B2 (fr)
EP (1) EP3212647B1 (fr)
JP (1) JP6505222B2 (fr)
KR (1) KR101978899B1 (fr)
CN (1) CN107001358A (fr)
AU (1) AU2015340215B2 (fr)
BR (1) BR112017008312A2 (fr)
CA (1) CA2962917C (fr)
MX (1) MX2017005346A (fr)
NZ (1) NZ730475A (fr)
RU (1) RU2684396C2 (fr)
SG (1) SG11201702075QA (fr)
WO (1) WO2016068580A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3359154B1 (fr) * 2015-10-08 2021-05-26 Suzhou Yunxuan Yiyao Keji Youxian Gongsi Inhibiteurs de la voie de signalisation wnt et leurs applications thérapeutiques
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
EA201992780A1 (ru) 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
CN112119065B (zh) * 2018-07-13 2024-01-23 四川科伦博泰生物医药股份有限公司 苯并二氮杂环类化合物、其制备方法及用途
KR102638962B1 (ko) 2020-01-31 2024-02-20 구미아이 가가쿠 고교 가부시키가이샤 3-알콕시벤조산 아미드 유도체 및 유해생물 방제제
WO2021198188A1 (fr) 2020-03-30 2021-10-07 Enyo Pharma Dérivés de quinazolinone et leurs utilisations pour le traitement d'un cancer
WO2021198191A1 (fr) 2020-03-30 2021-10-07 Enyo Pharma Dérivés de quinazolinone et leurs utilisations pour le traitement d'un cancer
EP4313300A1 (fr) * 2021-03-31 2024-02-07 Duke Street Bio Limited Composé pharmaceutique

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939421A (en) * 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
GB9909135D0 (en) * 1999-04-22 1999-06-16 Univ Wales Medicine Cystic fibrosis medicaments
BR0214414A (pt) * 2001-11-26 2004-09-14 Dsm Ip Assets Bv Processo para recuperar caprolactama
FR2846657B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7232824B2 (en) * 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
NZ546477A (en) * 2006-04-07 2009-04-30 Auckland Uniservices Ltd 4-Alkylamino-2-(heterocyclic)quinazolines and their use in cancer therapy
AU2012284088B2 (en) * 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
BR112015007061B1 (pt) * 2012-09-28 2022-10-04 Cancer Research Technology Limited Composto, composição farmacêutica e uso do composto
WO2014055634A1 (fr) 2012-10-02 2014-04-10 Yale University Identification de petites molécules inhibitrices d'histone déméthylase à de domaine jumonji 1a (jarid1a) et 1b (jarid1b) interactif riche en at,
MD20150043A2 (ro) 2012-10-02 2015-08-31 Epitherapeutics Aps Inhibitori ai histon-demetilazelor
WO2014087165A1 (fr) * 2012-12-06 2014-06-12 University Of Bath Inhibiteurs de tankyrase
EP3170811A1 (fr) 2013-02-27 2017-05-24 Gilead Sciences, Inc. Composé d'ethyl pyridine-4-carboxylate ester comme inhibiteur d'histone-déméthylases
JP6320506B2 (ja) 2013-03-12 2018-05-09 セルジーン クオンティセル リサーチ,インク. ヒストンデメチラーゼ阻害剤
CN105980386B (zh) 2013-03-13 2021-08-13 基因泰克公司 吡唑并化合物及其用途
PL2970211T3 (pl) 2013-03-15 2018-01-31 Quanticel Pharmaceuticals Inc Inhibitory demetylazy histonowej
WO2015035062A1 (fr) 2013-09-05 2015-03-12 Genentech, Inc. Composés antiprolifératifs
CN103694255A (zh) * 2014-01-09 2014-04-02 华中师范大学 吡啶并噁嗪酮和吡啶并嘧啶酮类化合物及其制备方法与应用
TWI675836B (zh) * 2014-03-25 2019-11-01 美商伊格尼塔公司 非典型蛋白質激酶c之氮雜喹唑啉抑制劑

Also Published As

Publication number Publication date
RU2017113007A3 (fr) 2018-11-29
CN107001358A (zh) 2017-08-01
NZ730475A (en) 2018-09-28
KR20170072943A (ko) 2017-06-27
JP2017533215A (ja) 2017-11-09
WO2016068580A2 (fr) 2016-05-06
US9834550B2 (en) 2017-12-05
KR101978899B1 (ko) 2019-05-15
MX2017005346A (es) 2017-08-02
BR112017008312A2 (pt) 2017-12-19
US20160122343A1 (en) 2016-05-05
RU2684396C2 (ru) 2019-04-09
EP3212647B1 (fr) 2019-04-03
RU2017113007A (ru) 2018-11-29
AU2015340215B2 (en) 2018-11-15
EP3212647A4 (fr) 2018-04-18
EP3212647A2 (fr) 2017-09-06
CA2962917A1 (fr) 2016-05-06
CA2962917C (fr) 2019-04-30
JP6505222B2 (ja) 2019-04-24
WO2016068580A3 (fr) 2016-08-18
AU2015340215A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
IL281264B (en) Complete activity modulation
SG11201702075QA (en) Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
HRP20180641T1 (hr) Pirolidinski gpr40 modulatori za liječenje bolesti kao što je dijabetes
EP3139943A4 (fr) Combinaisons de composés modulant nmdar
EP3143060B8 (fr) Catalyseurs pour la synthèse de composés d'oxazolidinone
ZA201702720B (en) 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as sgrm modulators
PL3359556T3 (pl) Modulowanie aktywności gamma-c-cytokin
GB201412000D0 (en) Catalytic reactors
EP3222212A4 (fr) Pastille pour électrodes
IL248670A0 (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
EP3303347A4 (fr) Modulation de h3k9me3 utilisée pour améliorer la fonction cognitive
EP3097203A4 (fr) Coupon de tissu destiné à l'essai de l'activité de la lipase
IL272732A (en) activity modulator
EP3106219A4 (fr) Catalyseur à support carboné
SG11201701400PA (en) Catalyst configuration for increased hydrocracking activity
GB201411477D0 (en) Catalytic reactors
TH1501005032A (th) วัสดุเร่งปฏิกิริยาสำหรับออกซิเดชันของ no